>>Signaling Pathways>> Neuroscience>> Pain Research>>Prochlorperazine (maleate)

Prochlorperazine (maleate)

Catalog No.GC44687

Prochlorperazine is a dopamine D2 receptor antagonist with Ki values of 4.7 and 2.9 nM for rat recombinant D2 receptors in CHO cells and rat striatal membranes, respectively.

Products are for research use only. Not for human use. We do not sell to patients.

Prochlorperazine (maleate) Chemical Structure

Cas No.: 1984/2/6

Size 가격 재고 수량
50mg
US$42.00
재고 있음
100mg
US$80.00
재고 있음
250mg
US$188.00
재고 있음
500mg
US$332.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Prochlorperazine is a dopamine D2 receptor antagonist with Ki values of 4.7 and 2.9 nM for rat recombinant D2 receptors in CHO cells and rat striatal membranes, respectively. It also binds to rat recombinant D3 receptors expressed in CHO cells (Ki = 35 nM) and to the serotonin (5-HT) receptor subtype 5-HT3 in N1E-115 mouse neuroblastoma cell membranes (Ki = 1,200 nM). Prochlorperazine (2 mg/kg) increases the latency to paw licking in a hot plate test, indicating analgesia, an effect that is blocked by antisense oligonucleotides against the M1 muscarinic receptor. It also inhibits emesis induced by apomorphine in dogs (ED50 = 0.34 mg/kg). Formulations containing prochlorperazine have been used in the treatment of psychotic disorders and as antiemetics.

리뷰

Review for Prochlorperazine (maleate)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Prochlorperazine (maleate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.